drugset

Drugs / RSO-021

Follow last change Jul 2026 re-read 3 minutes ago

RSO-021

Developed for: malignant pleural mesothelioma
Investigated by: RS Oncology LLC

Trials 1

today NCT05278975 · Ph 1/2

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT05278975	Mar 2022 → Apr 2025	malignant pleural mesothelioma	RS Oncology LLC	Unknown	Met primary

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2026-07-14	RS Oncology LLC	Results RS Oncology's PRX3 Inhibitor (RSO-021) Shows Promise in Fight Against Deadly Mesothelioma, Rooted in Discovery Science from the University of Vermont rsoncology.com ↗ Phase 1 Clinical Trial Shows 67% Disease Control

All press releases naming this drug 4 releases

Date	Issuer	Release
2026-07-14	RS Oncology LLC	RS Oncology's PRX3 Inhibitor (RSO-021) Shows Promise in Fight Against Deadly Mesothelioma, Rooted in Discovery Science from the University of Vermont rsoncology.com ↗
2024-03-29	RS Oncology LLC	RS Oncology to present translational data identifying potential biomarkers associated with RSO-021 anticancer activity rsoncology.com ↗
2024-02-01	RS Oncology LLC	RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung rsoncology.com ↗
2023-04-15	RS Oncology LLC	AACR 2023, RSO-021, a first-in-class treatment rsoncology.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	RSO-021	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05278975 ↗
Modality	Peptide	“a naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class” NCT05278975 ↗
Route	Other	“after intrapleural (IP) administration” NCT05278975 ↗